Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma

nasopharyngeal cancer.

  • 0 views
  • 22 Jan, 2021
  • 1 location
Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma

nasopharyngeal carcinoma.

  • 0 views
  • 24 Jan, 2021
  • 1 location
Programmed Death-1 (PD-1) Antibody Combined With IMRT in Recurrent Nasopharyngeal Carcinoma Patients

recurrent nasopharyngeal carcinoma patients.

  • 0 views
  • 24 Jan, 2021
  • 12 locations
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

the rate of disease progression and improve the survival outcome of patients with unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with concurrent chemo-radiotherapy

iv infusion
immunomodulator
recurrent nasopharyngeal carcinoma
measurable disease
carcinoma
  • 0 views
  • 25 Jan, 2021
  • 6 locations
Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma

This study aims at exploring whether plasma radiofrequency ablation at low temperature is associated with better survival outcome in localized recurrent nasopharyngeal carcinoma by conducting a

cancer
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma

This is a single-arm, non-randomised study including patients with EBER positive nasopharyngeal carcinoma with recurrent or metastatic disease not amenable to curative treatment, who have received at least 1 regimen of platinum containing chemotherapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma

Gemcitabine plus cisplatin (GC) is more effective than fluorouracil plus cisplatin in the treatment of recurrent or metastatic NPC (R/M-NPC). GC is the standard first-line chemotherapy regimen for this population. However, the median progression-free survival was only 7 months for GC regimen. Anlotinib is a kinase inhibitor of receptor tyrosine …

  • 0 views
  • 22 Jan, 2021
  • 1 location
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

The purpose of this study is to determine whether concurrent chemotherapy and IMRT is effective in the treatment of locally stage T3/T4 recurrent nasopharyngeal carcinoma patients compared with

  • 0 views
  • 23 Jan, 2021
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

This is an open-label, single center, phase I trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.

gemcitabine
measurable disease
platinum-based chemotherapy
carcinoma
toripalimab
  • 0 views
  • 24 Jan, 2021
  • 1 location
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.

apatinib
camrelizumab
metastatic nasopharyngeal carcinoma
measurable disease
carcinoma
  • 0 views
  • 25 Jan, 2021
  • 1 location